MapLight Therapeutics (MPLT) Change in Accured Expenses (2024 - 2025)

MapLight Therapeutics recorded quarterly Change in Accured Expenses of $1.1 million in Q4 2025, down 6.72% quarter-over-quarter from $1.2 million in Q4 2024, and down 6.72% year-over-year from $1.2 million in Q4 2024.

MapLight Therapeutics' Change in Accured Expenses history runs 2 years deep, the most recent figure standing at $1.1 million for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 931,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 70.50 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 107.70 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -176.03 Mn
10 MapLight Therapeutics 254.43 Mn 254.43 Mn - 1.12 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.12 Mn
Dec 31, 2025 1.12 Mn
Dec 31, 2024 1.21 Mn
Dec 31, 2024 1.21 Mn